Quality and Effectiveness of Thrombolytic Care During Inter-hospital Transfer ("Drip-Ship") With Air Ambulance Services
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Iowa
- Enrollment
- 76
- Locations
- 1
- Primary Endpoint
- Percentage of Participants With a rtPA Protocol Violation
Study Overview
Brief Summary
Evaluation of ischemic stroke patients receiving tissue plasminogen activator (rtPA) during air ambulance transfer
Detailed Description
The purpose of our study is to evaluate the effect of air ambulance transport on patients presenting with an ischemic stroke and receive tissue plasminogen activator (rtPA). Primary outcome will be the evaluation of air ambulance transfer and if it leads to protocol violations or significant delays in therapy. Protocol violations include inaccurate dosing or preparation at the outside hospital, uncontrolled blood pressure before and during the flight, unnecessary medication administration before and during the flight and adverse events (intracranial bleeding, allergic reaction) associated with transfer process. Additional evaluation will include the effects of vibration of the air ambulance and its effects on the lytic activity of rtPA. rtPA is not supposed to be significantly agitated after it is prepared in solution and there is significant vibration and agitation during air ambulance transfer.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Patients who received tissue plasminogen activator for acute ischemic stroke
- •presented directly to comprehensive stroke center or were transferred by our air ambulance service
Exclusion Criteria
- •Transferred by another air ambulance service or ground ambulance
Arms & Interventions
Intervention/Transfer
Patients who are transferred via air ambulance to a comprehensive stroke center
Intervention: Tissue Plasminogen Activator (Drug)
Control
Patients presenting directly to the comprehensive stroke center
Intervention: Tissue Plasminogen Activator (Drug)
Outcomes
Primary Outcomes
Percentage of Participants With a rtPA Protocol Violation
Time Frame: 24 hours
Protocol violations can include any of the following recorded outcomes: inaccurate dosing or preparation at the outside hospital, uncontrolled blood pressure before and during the flight, unnecessary medication administration before and during the flight, intracranial bleeding, and angioedema
Secondary Outcomes
- Average Time to rtPA(24 hours)
Investigators
Brett A Faine
Clinical Pharmacy Specialist
University of Iowa
